Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04923776 · ClinicalTrials.gov registry record · Phase 2
Liver Directed RT + Chemo-immunotherapy for ES-SCLC
A Phase 2 study, sponsored by Brian Henick, MD.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT04923776: Clinical Trial Phase 2 study, sponsored by Brian Henick, MD.
NCT04923776 is a Phase 2 study that was terminated before completion, run by Brian Henick, MD. The registered enrollment target is 2 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04923776, a Phase 2 study, was terminated before completion, sponsored by Brian Henick, MD.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate whether radiation treatment directed at liver metastases can be safely added to standard of care treatment for extensive stage small cell lung cancer (ES-SCLC). The current standard treatment for people who have ES-SCLC is chemotherapy including drugs called carboplatin and etoposide, that is combined with a type of immunotherapy called atezolizumab. However, patients with liver involvement of their ES-SCLC don't respond as well to this treatment. The study aims to answer whether adding radiation directed at liver metastases can improve responses to standard chemo-immunotherapy in this patient population. All study participants will get the same study intervention, which will be chemo-immunotherapy and radiation therapy.
Primary Outcome
Progression free survival rate at 6 months will be measured to assess the efficacy of liver-directed SBRT when added to standard of care atezolizumab + chemotherapy. 6-month PFS rate will be defined as the proportion of patients that are progression free and alive at 6 months from the start of treatment.
Interventions
- DRUG Carboplatin
- DRUG Atezolizumab
- DRUG Etoposide
- RADIATION Stereotactic Body Radiation Therapy (SBRT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2021-09-20 |
| Est. Completion | 2023-12-23 |
| Phase | Phase 2 |
Why NCT04923776 stopped before completion
NCT04923776 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT04923776 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04923776 about?
NCT04923776 is a clinical study titled "Liver Directed RT + Chemo-immunotherapy for ES-SCLC". The purpose of this study is to evaluate whether radiation treatment directed at liver metastases can be safely added to standard of care treatment for extensive stage small cell lung cancer (ES-SCLC). The current standard treatment for people who have ES-SCLC is chemotherapy including drugs called ...
What is the current status of trial NCT04923776?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2021-09-20. Estimated completion is 2023-12-23.
What interventions are being tested in trial NCT04923776?
The interventions under investigation include: Carboplatin (DRUG), Atezolizumab (DRUG), Etoposide (DRUG), Stereotactic Body Radiation Therapy (SBRT) (RADIATION).
Who is sponsoring clinical trial NCT04923776?
This trial is sponsored by Brian Henick, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04923776's enrollment target sits among peer trials
2 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI